"The side effects of this vaccine are minimal compared to those people who will be infected with the virus," said Thomas Lönngren, Executive Director of the European Medicines Agency, explaining why the agency had fast tracked clinical approval for the vaccines.
„Vakcīnu blaknes ir minimālas, salīdzinājumā ar to, cik ļoti veselībai varētu kaitēt inficēšanās ar „cūku gripu"," skaidroja Thomas Lönngren, pamatodams lēmumu pēc iespējas ātrāk virzīt vakcīnu pieejamību tirgū.